Financing channel feed

Abcuro reels in $155M to test an­ti­body's po­ten­tial in rare mus­cle dis­ease, set­ting biotech's 2026 BLA plans

Last year
Startups

Ra­dio­phar­ma­ceu­ti­cal biotech Ra­dio­net­ics in fundrais­ing mode with $54.2M so far

Last year

Taysha rais­es $150M PIPE, shares sin­gle pa­tient da­ta on Rett syn­drome gene ther­a­py

Last year
R&D
Cell/Gene Tx

Mary­land biotech Geor­gia­mune nabs $75M to fund three can­cer, au­toim­mune clin­i­cal tri­als 

Last year
Startups

RNA start­up ADARx rais­es $200M from Bain, TCGX to bring RNAi 'to the next lev­el'

Last year

Flag­ship start­up All­tr­na rais­es $109M for tR­NA ther­a­pies that re­store miss­ing pro­teins

Last year

Mi­rati an­nounces CEO res­ig­na­tion, then a $300M pub­lic of­fer­ing af­ter dis­clos­ing clin­i­cal plans

Last year
People

Nas­daq threat­ens to delist Taysha Gene Ther­a­pies

Last year

Po­sei­da lines up an­oth­er al­lo­gene­ic CAR-T part­ner, al­ly­ing with Astel­las on sol­id tu­mors

Last year
Cell/Gene Tx

Play­ground Glob­al, a16z back $26M seed for RNA edit­ing start­up aim­ing to ad­dress mul­ti­ple mu­ta­tions with sin­gle shot

Last year
Startups

Ex­clu­sive: Tech VC firm Play­ground Glob­al deep­ens biotech fo­cus, hires for­mer a16z part­ner with next fund com­ing

Last year
People

Kyver­na Ther­a­peu­tics adds $60M to the bank as it pre­pares to show­case ear­ly CAR-T da­ta in lu­pus nephri­tis

Last year
Cell/Gene Tx

Steve Job­s' son to lead Emer­son Col­lec­tive's on­col­o­gy-fo­cused VC firm Yosemite

Last year
Startups

CG On­col­o­gy reels in $105M crossover for po­ten­tial late 2024 blad­der can­cer drug fil­ing

Last year
Startups

Long­wood launch­es start­up Solu with drug can­di­dates from GSK and $31M to start

Last year
Startups

PureTech Health snags $11.4M from DOD to test hor­mone drug in rare brain dis­ease

Last year

Pe­ter Hecht’s $81M pledge to sal­vage Cy­cle­ri­on as­sets nabs Po­laris sup­port

Last year
Startups

Uro­Gen nabs $120M to sup­port po­ten­tial 2024 NDA fil­ing, launch of blad­der can­cer chemo gel

Last year

The vet­er­an crew at Medicxi is back with a new $400M fund and an up­beat as­sess­ment of what's com­ing

Last year
Startups
Bioregnum

Jim Mom­tazee's Pa­tient Square leads $150M+ ad­di­tion to Kriya Ther­a­peu­tic­s' 'main­stream' gene ther­a­py am­bi­tions

Last year
Startups
Cell/Gene Tx

SPAC bust: ARCH, Deer­field and Sec­tion 32 can­cel their $200M life sci­ences bet

Last year

Lon­za cites biotech fund­ing slow­down as it low­ers sales out­look for the year

Last year
Manufacturing

Part­nered with Lil­ly, TVM Cap­i­tal and Tillotts fund oral in­flam­ma­to­ry bow­el dis­ease drug with up to $28M

Last year
Startups

Turn­stone Bi­o­log­ics rides biotech's IPO train in Fri­day de­but

Last year
Startups
First page Previous page 29303132333435 Next page Last page
A service from the Financial Times